125 related articles for article (PubMed ID: 9893190)
1. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
2. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.
Cates CJ; Wieland LS; Oleszczuk M; Kew KM
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD010314. PubMed ID: 24504983
[TBL] [Abstract][Full Text] [Related]
3. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.
Walters EH; Walters JA; Gibson PW
Cochrane Database Syst Rev; 2002; 2002(4):CD003901. PubMed ID: 12519616
[TBL] [Abstract][Full Text] [Related]
4. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
Cates CJ; Lasserson TJ
Sao Paulo Med J; 2010; 128(5):310-1. PubMed ID: 21181075
[TBL] [Abstract][Full Text] [Related]
5. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
Cates CJ; Lasserson TJ
Cochrane Database Syst Rev; 2012 Mar; 3(3):CD007695. PubMed ID: 22419326
[TBL] [Abstract][Full Text] [Related]
6. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol.
Bateman ED; Fairall L; Lombardi DM; English R
Respir Res; 2006 Jan; 7(1):13. PubMed ID: 16433920
[TBL] [Abstract][Full Text] [Related]
7. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials.
Haney S; Hancox RJ
Respir Res; 2007 Mar; 8(1):19. PubMed ID: 17341317
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of As-Needed Formoterol in Asthma Patients Taking Inhaled Corticosteroid (ICS)-Formoterol or ICS-Salmeterol Maintenance Therapy.
Reddel HK; Brusselle G; Lamarca R; Gustafson P; Anderson GP; Jorup C
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2104-2114.e3. PubMed ID: 37054881
[TBL] [Abstract][Full Text] [Related]
9. Regular treatment with formoterol for chronic asthma: serious adverse events.
Cates CJ; Cates MJ
Cochrane Database Syst Rev; 2012 Apr; 4(4):CD006923. PubMed ID: 22513944
[TBL] [Abstract][Full Text] [Related]
10. Methacholine challenge as a clinical bioassay of pulmonary delivery of a long-acting β₂-adrenergic agonist.
Prabhakaran S; Shuster J; Ahrens R; Hendeles L
Pharmacotherapy; 2011 May; 31(5):449-57. PubMed ID: 21923426
[TBL] [Abstract][Full Text] [Related]
11. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.
Tomlinson HS; Corlett SA; Allen MB; Chrystyn H
Br J Clin Pharmacol; 2005 Dec; 60(6):605-10. PubMed ID: 16305584
[TBL] [Abstract][Full Text] [Related]
12. Fluticasone/formoterol association favors long-lasting decrease in bronchial reactivity to methacholine and weekly PEF variability.
Cortese S; Gatta A; Della Valle L; Mangifesta R; Di Giampaolo L; Cavallucci E; Petrarca C; Paganelli R; Di Gioacchino M
Int J Immunopathol Pharmacol; 2016 Dec; 29(4):769-774. PubMed ID: 27272161
[TBL] [Abstract][Full Text] [Related]
13. Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.
Cardet JC; Jiang X; Lu Q; Gerard N; McIntire K; Boushey HA; Castro M; Chinchilli VM; Codispoti CD; Dyer AM; Holguin F; Kraft M; Lazarus S; Lemanske RF; Lugogo N; Mauger D; Moore WC; Moy J; Ortega VE; Peters SP; Smith LJ; Solway J; Sorkness CA; Sumino K; Wechsler ME; Wenzel S; Israel E;
J Allergy Clin Immunol; 2019 Aug; 144(2):416-425.e7. PubMed ID: 30872116
[TBL] [Abstract][Full Text] [Related]
14. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Palmer CN; Lipworth BJ; Lee S; Ismail T; Macgregor DF; Mukhopadhyay S
Thorax; 2006 Nov; 61(11):940-4. PubMed ID: 16772309
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effectiveness and safety of formoterol versus salmeterol in the treatment of patients with asthma: A systematic review and meta-analysis.
Velayati A; Hosseini SA; Sari AA; Mohtasham F; Ghanei M; Yaghoubi M; Majdzadeh R
J Res Med Sci; 2015 May; 20(5):483-90. PubMed ID: 26487878
[TBL] [Abstract][Full Text] [Related]
16. WITHDRAWN: Inhaled bronchodilators for cystic fibrosis.
Halfhide C; Evans HJ; Couriel J
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD003428. PubMed ID: 26866910
[TBL] [Abstract][Full Text] [Related]
17. Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and beta2-agonist use.
Hastie AT; Wu M; Foster GC; Hawkins GA; Batra V; Rybinski KA; Cirelli R; Zangrilli JG; Peters SP
Respir Res; 2006 Feb; 7(1):25. PubMed ID: 16480498
[TBL] [Abstract][Full Text] [Related]
18. Amitriptyline inhibits bronchoconstriction and directly promotes dilatation of the airways.
Hempel P; Klein V; Michely A; Böll S; Rieg AD; Spillner J; Braunschweig T; von Stillfried S; Wagner N; Martin C; Tenbrock K; Verjans E
Respir Res; 2023 Oct; 24(1):262. PubMed ID: 37907918
[TBL] [Abstract][Full Text] [Related]
19. Inhaled β-agonist does not modify sympathetic activity in patients with COPD.
Haarmann H; Mohrlang C; Tschiesner U; Rubin DB; Bornemann T; Rüter K; Bonev S; Raupach T; Hasenfuß G; Andreas S
BMC Pulm Med; 2015 Apr; 15():46. PubMed ID: 25924990
[TBL] [Abstract][Full Text] [Related]
20. Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma.
Short PM; Williamson PA; Anderson WJ; Lipworth BJ
Am J Respir Crit Care Med; 2013 Jun; 187(12):1308-14. PubMed ID: 23593932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
